Given that the DOR of present BCMA Si-CAR T-cell therapy in MM is far from satisfactory, Bi-CAR T-cell therapy targeting other antigens together with BCMA might warrant further investigation. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.